Share Dilution
-
Prospera Provides Financing Update
Prospera Energy increased its non-brokered convertible debenture offering to CAD $4.0 million, targeting a close date on or before December 14, 2025, pending TSXV approval. Proceeds will fund well reactivation, production optimization, and working capital. The debenture includes a 12% interest rate and conversion options into units at CAD $0.05/$0.10, with warrants. Prospera will also issue 1,000,000 shares to settle $82,144 in payables. While the offering aims to boost production, investors face potential dilution from conversion features and share issuance.
-
VIQ Solutions Completes Oversubscribed Private Placement
VIQ Solutions (VQSSF) closed the second tranche of an upsized private placement on November 5, 2025, raising approximately C$585,000. The company issued 3,146,063 units at C$0.186 per unit, each including a share and a warrant exercisable at C$0.190 until 2030. Total proceeds from the placement exceed C$3.0 million. Proceeds will fund technology innovations, organic growth, acquisitions, and restructuring. The issuance of new units will cause some share dilution.
-
Erayak Power Solution Group Announces $7 Million Registered Direct Offering
Erayak Power Solution Group (RAYA) announced a $7 million registered direct offering, selling 107,692,307 Class A ordinary shares at $0.065 each. The offering, expected to close around August 1, 2025, includes pre-funded warrants with a $0.0001 exercise price. Craft Capital Management is the sole placement agent. This infusion of capital aims to bolster Erayak’s financial position, but the issuance of a large number of new shares will likely cause significant dilution for existing shareholders.
-
SeaStar Medical Announces $4 Million Registered Direct Offering Priced at the Market Under NASDAQ Rules
SeaStar Medical raised $4M through a registered direct offering of 5.24 million shares priced at $0.763 each, with five-year warrants exercisable at $0.638. The capital infusion supports commercialization of its FDA-approved pediatric AKI device and adult trials, but triggers 33% equity dilution. Analysts note the structure creates potential stock price pressure, as warrants priced 16% below offering prices might constrain valuations. While addressing immediate liquidity needs, the conventional equity approach suggests urgency in funding operations rather than strategic growth initiatives, with funds allocated vaguely for corporate purposes.